Last reviewed · How we verify
Long term androgen deprivation
Long-term androgen deprivation therapy suppresses testosterone production to inhibit the growth of androgen-dependent prostate cancer cells.
Long-term androgen deprivation therapy suppresses testosterone production to inhibit the growth of androgen-dependent prostate cancer cells. Used for Metastatic hormone-sensitive prostate cancer, Locally advanced prostate cancer (in combination with radiation therapy).
At a glance
| Generic name | Long term androgen deprivation |
|---|---|
| Also known as | Neoadjuvant, concomitant and adjuvant |
| Sponsor | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
| Drug class | Androgen deprivation therapy (ADT) |
| Target | Androgen receptor signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This therapeutic approach reduces circulating androgens through chemical or surgical castration, depriving prostate cancer cells of the hormonal signals required for proliferation. By maintaining sustained low testosterone levels over extended periods, the treatment aims to control disease progression in hormone-sensitive prostate cancer. This is a standard endocrine therapy approach for advanced prostate cancer management.
Approved indications
- Metastatic hormone-sensitive prostate cancer
- Locally advanced prostate cancer (in combination with radiation therapy)
Common side effects
- Hot flashes
- Erectile dysfunction
- Decreased libido
- Gynecomastia
- Bone loss/osteoporosis
- Fatigue
- Weight gain
- Metabolic syndrome
Key clinical trials
- PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
- Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer (PHASE2)
- The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
- Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer (PHASE2, PHASE3)
- MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) (PHASE2)
- Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients (NA)
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: